The Russian Sovereign Fund has announced that it has reached an agreement with the Indian pharmaceutical group Hetero for the production from 2021 of more than 100 million annual doses of the Russian vaccine against the coronavirus called Sputnik V.
“Hetero, one of the main Indian manufacturers of generic drugs, has agreed to produce in India more than 100 million doses per year” of the Sputnik V vaccine, the Russian Sovereign Fund, which financed its development, said on November 27, specifying that production should start in early 2021.
“Thanks to our cooperation with Hetero, we will be able to significantly increase the production capacity and provide the Indian population with an effective solution in this difficult period of the pandemic”, commented the head of the fund, Kirill Dmitriev, quoted in the press release.
As the Russian press agency TASS reminds us, the Sputnik V vaccine – developed by the National Institute for Epidemiology and Microbiology of Gamaleya – was registered on August 11 by the Russian Ministry of Health. It is therefore the first vaccine registered in the world against Covid-19.
It was the subject of clinical trials in June and July. On August 15, the Russian Ministry of Health announced the start of its production. The third stage, the post-approval of clinical trials of the vaccine, began on August 25.
Also according to TASS citing results of interim analyzes, the effectiveness of the Russian vaccine exceeds the rate of 95% 42 days after the first dose, provided that the patient receives the second dose. The Russian Sovereign Fund specifies that “requests” for more than 1.2 billion doses of Sputnik V have been made by “more than 50 countries”. In addition to India, the vaccine must notably be produced in Brazil, China or South Korea.